Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Phase 1 Withdrawn
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
Phase NA Withdrawn
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Phase 1 Withdrawn
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 Withdrawn
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
Phase 2 Withdrawn
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
Phase 1 Withdrawn
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Phase 1 Withdrawn
Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study
Phase NA Withdrawn
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
Phase 2 Withdrawn
DEC-C and Thioguanine for R/R AML
Phase 2 Withdrawn
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
Phase 1/2 Withdrawn
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Withdrawn
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Withdrawn
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Phase 1/2 Withdrawn
Antimicrobial Revision in Persistent Febrile Neutropenia
Phase 4 Withdrawn
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
Phase 1 Withdrawn
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 2 Withdrawn
Tislelizumab with Azacitidine in the Treatment of R/R AML
Phase 1/2 Withdrawn
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Withdrawn
Pediatric AML
Phase 1 Withdrawn
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Phase 2 Withdrawn
LAMIPA
Withdrawn
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Phase 1/2 Withdrawn
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
Withdrawn
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Phase 1/2 Withdrawn
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Phase 1 Withdrawn
MAGROLIC
Phase 2 Withdrawn
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Phase 2 Withdrawn
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Phase 1/2 Withdrawn
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Phase 1 Withdrawn
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Phase 1 Withdrawn
Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia
Phase NA Withdrawn
BISECT
Phase 1 Withdrawn
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Phase 1/2 Withdrawn
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
Phase 1 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Phase 1/2 Withdrawn
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Withdrawn
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Phase 1 Withdrawn
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
Phase 1 Withdrawn
Acute Myeloid Leukemia Real World Treatment Patterns
Withdrawn
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
Phase 1 Withdrawn
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Phase 2 Withdrawn
DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US
Withdrawn
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Phase 1 Withdrawn
Diagnosis and Treatment of Periodontal Disease in Patients With AML
Phase NA Withdrawn
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Phase 2 Withdrawn
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Phase 1/2 Withdrawn
2019-KOE-001
Phase 2 Withdrawn
HERKULES-4
Phase 1/2 Withdrawn